A new vaccine to prevent infections from Pseudomonas aeruginosa.
An intranasal room stable vaccine formulation to prevent Pseudomonas aeruginosa (R21AI169691)
This study is working on a new nasal vaccine to help protect people, especially those with cystic fibrosis or serious wounds, from infections caused by a tough germ called Pseudomonas aeruginosa, which can be hard to treat with antibiotics.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10918223 on NIH RePORTER |
What this research studies
This research focuses on developing a stable intranasal vaccine formulation aimed at preventing infections caused by Pseudomonas aeruginosa, a bacterium that poses significant risks to patients with conditions like cystic fibrosis and severe wounds. The approach involves creating a nanoparticle suspension that can effectively stimulate the immune system to combat various strains of this pathogen before they can establish harmful biofilms. The study aims to address the growing issue of antibiotic resistance by providing a preventive measure against this opportunistic infection.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with cystic fibrosis, burn injuries, or those who are critically ill and at risk of Pseudomonas aeruginosa infections.
Not a fit: Patients who do not have risk factors for Pseudomonas aeruginosa infections, such as those without underlying health conditions or younger individuals with no history of severe illness, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the incidence of severe infections caused by antibiotic-resistant Pseudomonas aeruginosa.
How similar studies have performed: While there are ongoing efforts to develop vaccines against Pseudomonas aeruginosa, this specific approach using a stable nanoparticle formulation is novel and has not been extensively tested in prior studies.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Picking, Wendy L. — University of Missouri-Columbia
- Study coordinator: Picking, Wendy L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.